Abiopharma

🔍 Geist William (Executive)

Company: BIO-TECHNE Corp (TECH)

Report Date: 2026-08-15

Detailed Transactions and Holdings:

• Acquired 6,416 shares of Common Stock (Direct)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 26,919.00 | transaction_form_type: 4
• Sold 1,976 shares of Common Stock at $72.4 per share (Direct)
  Date: 2026-08-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 24,943.00 | transaction_form_type: 4
• Sold 567 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,507.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 8,507 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 22,898 shares of Performance Stock Options (Right to Buy) at $84.61 per share (Derivative)
  Date: 2026-08-15 | Code: D | equity_swap_involved: 0 | shares_owned_after: 1,526.00 | transaction_form_type: 4 | Footnotes: F5, F5
• Sold 2,623 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,623.00 | transaction_form_type: 4 | Footnotes: F1, F7, F7
• Sold 3,226 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,452.00 | transaction_form_type: 4 | Footnotes: F1, F10, F10
• Holds 15,912 shares of Stock Options (Right to Buy) at $100.39 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2029-02-01 | shares_owned_after: 15,912.00 | Footnotes: F2
• Holds 29,600 shares of Stock Options (Right to Buy) at $94.52 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2029-08-15 | shares_owned_after: 29,600.00 | Footnotes: F2
• Holds 30,059 shares of Stock Options (Right to Buy) at $84.61 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2030-08-15 | shares_owned_after: 30,059.00 | Footnotes: F4
• Holds 15,738 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: H | shares_owned_after: 15,738.00 | Footnotes: F1, F6, F6
• Holds 21,204 shares of Stock Options (Right to Buy) at $74.91 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2034-08-15 | shares_owned_after: 21,204.00 | Footnotes: F8
• Holds 19,355 shares of Performance Restricted Stock Units (Derivative)
  Date: 2026-08-15 | Code: H | shares_owned_after: 19,355.00 | Footnotes: F1, F9, F9
• Holds 24,758 shares of Stock Options (Right to Buy) at $53.6 per share (Derivative)
  Date: 2026-08-15 | Code: H | Expires: 2035-08-15 | shares_owned_after: 24,758.00 | Footnotes: F11

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
• F2: 100% vested.
• F3: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited.
• F4: Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
• F5: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,526 performance options. The remainder of the performance options were forfeited.
• F6: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
• F7: 2,623 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
• F8: Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
• F9: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
• F10: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
• F11: Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.